Physician profile
Henry E Degroot
NPI 1346260411
$12,654.13
in general payments reported to CMS, 2019-2025
28 companies · $1,854 in 2025
The $1,854 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,121 · 2020: $755 · 2021: $1,255 · 2022: $1,667 · 2023: $2,407 · 2024: $2,596 · 2025: $1,854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,745 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,744.71 |
| Education | $112.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,406.39 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Regeneron Healthcare Solutions, INC. | $1,358.82 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $1,187.99 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $1,151.39 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Ucb, INC. | $883.19 | 2021-2025 | Bimzelx |
| Genzyme Corporation | $594.85 | 2020-2025 | |
| Amgen INC. | $594.51 | 2019-2024 | Otezla |
| Incyte Corporation | $562.15 | 2022-2025 | Opzelura, Opzelura |
| Genentech USA, INC. | $483.41 | 2019-2023 | Xolair |
| Novartis Pharmaceuticals Corporation | $407.23 | 2019-2025 | |
| Pfizer INC. | $365.64 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $296.90 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.35 | 2023-2025 | Spevigo |
| Arcutis Biotherapeutics, INC. | $227.62 | 2023-2024 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $213.57 | 2021-2025 | Sotyktu |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $195.50 | 2019-2024 | Adbry |
| Almirall LLC | $101.42 | 2024-2025 | Klisyri |
| Dermavant Sciences, INC. | $93.51 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $71.91 | 2019-2020 | |
| Organon LLC | $50.66 | 2025 | Vtama |
| Celgene Corporation | $38.71 | 2019 | |
| Merz North America, INC. | $29.47 | 2025 | |
| Mylan Institutional INC. | $26.17 | 2023 | |
| Biofrontera INC. | $23.99 | 2025 | |
| Janssen Biotech, INC. | $21.73 | 2023 | Simponi Aria, Simponi, Remicade |
| Dermira, INC. | $17.69 | 2019 | |
| Smith+Nephew, INC. | $15.29 | 2019 | |
| Prugen, INC. Pharmaceuticals | $5.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Degroot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.